NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced new clinical progress across the United States. This momentum directly supports the Company's strategy to accelerate global growth and expand patient access to advanced, minimally invasive therapies. Reinforcing the Company's market leadership in the western United States, Samer Nakhle, M.D., FACE, ECNU, Medical Director of Palm Medical Group in Las Vegas, Nevada

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians direct access to its innovative needle-based therapies for thyroid conditions. Baird Medical will join top interventionalists and surgeons to demonstrate how its proprietary technology treats benign nodules without th

NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the strategic commercial deployment of its technology at Bakersfield Memorial Hospital in California. This launch represents the first ablation case for Benign Thyroid Tumor (or "of its kind") in the vital central California hub of the San Joaquin Valley. This development reinforces Baird Medical's commitment to accelerating patient access to advanced care and solidifies the Company's expanding footprint in key U.S. regional markets.

NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the execution of premier clinical education programs in the United States and Japan. These strategic engagements reinforce Baird Medical's market leadership and accelerate its global expansion by establishing standardized clinical excellence for interventional thyroidology. In New York, the Company successfully facilitated an advanced training initiative at the

NEW YORK, Jan. 28, 2026  /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful conclusion of its Gynecological Microwave Ablation Masterclass in Shanghai. Led by Dr. Xiaoming Gong of Weheal, the program offered a rigorous curriculum designed to advance procedural expertise in the treatment of benign gynecological conditions using the Company's proprietary technology. The event featured a combination of expert-led didactic

NEW YORK, Jan. 26, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced a strategic partnership with Stonewood Key Capital, a wholly-owned comprehensive investment management enterprise from New Zealand. This collaboration positions the Hainan Free Trade Port as a pivotal hub for the Company's cross-border operations and supply chain, enabling more efficient capital allocation to accelerate the commercialization of its advanced medical solutions globally.

NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. During the conference week, the Company's leadership team, including U.S. CEO Mark Saxton, held a series of meetings with institutional investors and healthcare industry veterans. These discussions focused on Baird Medical's 2026 strategic priorities, specificall

NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in Microwave Ablation (MWA) technology, today announced it has reached key regulatory milestones with official product registrations from both the Medical Device Board (MDB) of Pakistan and the Ministry of Health of Vietnam. In Pakistan, the Company successfully executed its official product launch at the Armed Forces Institute of Radiology & Imaging (AFIRI). The launch was conducted under the professional guidance of Dr. Raza Raheem,

NEW YORK, Dec. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in Microwave Ablation (MWA) technology, today announced the establishment of a dedicated manufacturing base in the United States. This development marks a pivotal step in Baird Medical's transition from a specialized exporter to a comprehensive global medical technology enterprise. The decision to anchor production in North America is driven by the Company's rapid commercial success across over a dozen countries, including recent sign

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in Microwave Ablation (MWA) technology, recently concluded an advanced MWA training session in New Orleans. This initiative reinforces the Company's commitment to accelerating the adoption of minimally invasive therapies through strategic physician education. The specialized training program was led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine. The program provided advanced trai

6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

424B3 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

EFFECT - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

F-1/A - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

F-1/A - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

20-F - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

NT 20-F - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

F-1/A - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the appointment of Mark Saxton as Chief Executive Officer of its U.S. subsidiary. Mr. Saxton is a seasoned medical device executive with more than 25 years of commercial leadership experience, including a decade advancing intravascular RF ablation technologies. He will lead all U.S. operations, including sales, marketing, and market development, as Baird Medical

NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism. The prestigious academic event was hosted by the China-Japan Friendship Hospital in Beijing, China, from October 17-18, 2025. Chaired by Prof. Ming'an Yu, a leading authority in interventional medicine, the workshop served as a vital platform for the world's foremost experts to share